TY - JOUR
T1 - Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities
T2 - A multicenter real-world observational study
AU - Cherubini, Valentino
AU - Fargalli, Andrea
AU - Arnaldi, Claudia
AU - Bassi, Marta
AU - Bonfanti, Riccardo
AU - Patrizia Bracciolini, Giulia
AU - Cardella, Francesca
AU - Dal Bo, Sara
AU - Delvecchio, Maurizio
AU - Di Candia, Francesca
AU - Franceschi, Roberto
AU - Maria Galassi, Sabrina
AU - Gallo, Francesco
AU - Graziani, Vanna
AU - Iannilli, Antonio
AU - Mameli, Chiara
AU - Marigliano, Marco
AU - Minuto, Nicola
AU - Monti, Sara
AU - Mozzillo, Enza
AU - Pascarella, Filomena
AU - Predieri, Barbara
AU - Rabbone, Ivana
AU - Roppolo, Rosalia
AU - Schiaffini, Riccardo
AU - Tiberi, Valentina
AU - Tinti, Davide
AU - Toni, Sonia
AU - Scaramuzza, Andrea
AU - Vestrucci, Benedetta
AU - Gesuita, Rosaria
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/4
Y1 - 2024/4
N2 - Aims: To analyze metabolic outcomes, diabetes impact and device satisfaction in children and adolescents with type 1 diabetes in Italy who used different treatment modalities for diabetes care in a real-life context. Methods: In this multicenter, nationwide, cross-sectional study, 1464 participants were enrolled at a routine visit. The following treatment modalities were considered MDI + SMBG; MDI + CGM; Sensor Augmented Pump Therapy; predictive management of low glucose; Hybrid Closed Loop (HCL); Advanced Hybrid Closed Loop (AHCL). Health related quality of life was evaluated by the Italian version of the Diabetes Impact and Device Satisfaction Scale (DIDS) questionnaire. Results: Patients treated with AID systems were more likely to have HbA1c ≤ 6.5 %, higher percentage of time with glucose levels between 70 and 180 mg/dL, lower percentage of time with glucose levels above 180 mg/dL, higher device satisfaction, and reduced impact of diabetes. All the therapeutic modalities with respect to MDI + CGM, except for MDI + SMBG, contributed to increase the device satisfaction. HCL and AHCL respect to MDI + CGM were associated with lower diabetes impact. Conclusion: Real-life use of automated insulin delivery systems is associated with reduced type 1 diabetes impact, increased device satisfaction, and achievement of glycemic goals.
AB - Aims: To analyze metabolic outcomes, diabetes impact and device satisfaction in children and adolescents with type 1 diabetes in Italy who used different treatment modalities for diabetes care in a real-life context. Methods: In this multicenter, nationwide, cross-sectional study, 1464 participants were enrolled at a routine visit. The following treatment modalities were considered MDI + SMBG; MDI + CGM; Sensor Augmented Pump Therapy; predictive management of low glucose; Hybrid Closed Loop (HCL); Advanced Hybrid Closed Loop (AHCL). Health related quality of life was evaluated by the Italian version of the Diabetes Impact and Device Satisfaction Scale (DIDS) questionnaire. Results: Patients treated with AID systems were more likely to have HbA1c ≤ 6.5 %, higher percentage of time with glucose levels between 70 and 180 mg/dL, lower percentage of time with glucose levels above 180 mg/dL, higher device satisfaction, and reduced impact of diabetes. All the therapeutic modalities with respect to MDI + CGM, except for MDI + SMBG, contributed to increase the device satisfaction. HCL and AHCL respect to MDI + CGM were associated with lower diabetes impact. Conclusion: Real-life use of automated insulin delivery systems is associated with reduced type 1 diabetes impact, increased device satisfaction, and achievement of glycemic goals.
KW - Children and adolescents
KW - DIDS
KW - Diabetes technology
KW - Health related quality of life
KW - Treatment modalities
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85188544852&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2024.111621
DO - 10.1016/j.diabres.2024.111621
M3 - Article
SN - 0168-8227
VL - 210
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 111621
ER -